Nine-Country Study Shows Wide Variations in How Women With Early Breast Cancer Are Treated
ScienceDaily (Apr. 12, 2010) — A global study of nearly 10,000 women with early breast cancer has found wide variations in how they were treated, despite international consensus on best practice, according to the May issue of the British Journal of Surgery.
Researchers from Europe, Japan and America compared 9,779 women with an average age of 64 from 566 study sites in Belgium, France,...
* Substances may block estrogen production
* Not meant to replace aromatase inhibitor medicines
By JoAnne Allen
WASHINGTON, Jan 5 (Reuters) - Enzyme-blocking chemicals in pomegranates may reduce the risk of estrogen-fueled breast cancers, U.S. researchers said on Tuesday.
An acid found in pomegranates appears to block aromatase, an enzyme that converts androgen to estrogen, a hormone that plays a role in the development...
Pfizer Oncology to present early-stage research of investigational agents for cancer treatment
The Medical News
19. September 2009 01:32
Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer, updated study results from a Phase 3 study of Sutent® (sunitinib malate) in pancreatic neuroendocrine tumors (NET), and early-stage research of investigational...
WASHINGTON (Reuters) - A very low dose of estrogen might help women whose breast cancer has come back after treatment, researchers reported on Tuesday.
Even though most treatments are aimed at stopping estrogen from fueling tumors, the researchers said after years of this therapy the body may need some of the hormone to fight them off.
Their findings, published in the Journal of the American Medical Association, suggest a cheap...
Results from two separate studies have indicated that the aromatase agents Femara® (letrozole) and Aromasin® (exemestane) improve outcomes compared with tamoxifen (Nolvadex®) as initial therapy in early, hormone-positive breast cancer. These results were presented at the 2008 San Antonio Breast Cancer Symposium (SABCS).
Although aromatase inhibitors have been widely accepted as standard adjuvant endocrine therapy for hormone-positive breast cancers among eligible women, follow-up of...
